Role of immune-checkpoint inhibitors in lung cancer

Role of immune-checkpoint inhibitors in lung cancer

Immune checkpoint inhibitors, mainly drugs targeting the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen 4 (CTLA4) pathways, represent a remarkable advance in lung cancer treatment. Immune checkpoint inhibitors targeting PD-1 and PD-L1 are app...

Full description

Bibliographic Details
Main Authors: Prantesh Jain, Chhavi Jain, Vamsidhar Velcheti
Format: Article
Language:English
Published: SAGE Publishing 2018-01-01
Series:Therapeutic Advances in Respiratory Disease
Online Access:https://doi.org/10.1177/1753465817750075
id doaj-7849f4aa9dd24002822dc249bc672acd
record_format Article
spelling doaj-7849f4aa9dd24002822dc249bc672acd2020-11-25T03:07:37ZengSAGE PublishingTherapeutic Advances in Respiratory Disease1753-46662018-01-011210.1177/1753465817750075Role of immune-checkpoint inhibitors in lung cancerPrantesh JainChhavi JainVamsidhar VelchetiImmune checkpoint inhibitors, mainly drugs targeting the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen 4 (CTLA4) pathways, represent a remarkable advance in lung cancer treatment. Immune checkpoint inhibitors targeting PD-1 and PD-L1 are approved for the treatment of patients with non-small-cell lung cancer, with impressive clinical activity and durable responses in some patients. This review will summarize the mechanism of action of these drugs, the clinical development of these agents and the current role of these agents in the management of patients with lung cancer. In addition, the review will discuss the role of predictive biomarkers for optimal patient selection for immunotherapy and management of autoimmune side effects of these agents.https://doi.org/10.1177/1753465817750075
collection DOAJ
language English
format Article
sources DOAJ
author Prantesh Jain
Chhavi Jain
Vamsidhar Velcheti
spellingShingle Prantesh Jain
Chhavi Jain
Vamsidhar Velcheti
Role of immune-checkpoint inhibitors in lung cancer
Therapeutic Advances in Respiratory Disease
author_facet Prantesh Jain
Chhavi Jain
Vamsidhar Velcheti
author_sort Prantesh Jain
title Role of immune-checkpoint inhibitors in lung cancer
title_short Role of immune-checkpoint inhibitors in lung cancer
title_full Role of immune-checkpoint inhibitors in lung cancer
title_fullStr Role of immune-checkpoint inhibitors in lung cancer
title_full_unstemmed Role of immune-checkpoint inhibitors in lung cancer
title_sort role of immune-checkpoint inhibitors in lung cancer
publisher SAGE Publishing
series Therapeutic Advances in Respiratory Disease
issn 1753-4666
publishDate 2018-01-01
description Immune checkpoint inhibitors, mainly drugs targeting the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen 4 (CTLA4) pathways, represent a remarkable advance in lung cancer treatment. Immune checkpoint inhibitors targeting PD-1 and PD-L1 are approved for the treatment of patients with non-small-cell lung cancer, with impressive clinical activity and durable responses in some patients. This review will summarize the mechanism of action of these drugs, the clinical development of these agents and the current role of these agents in the management of patients with lung cancer. In addition, the review will discuss the role of predictive biomarkers for optimal patient selection for immunotherapy and management of autoimmune side effects of these agents.
url https://doi.org/10.1177/1753465817750075
work_keys_str_mv AT pranteshjain roleofimmunecheckpointinhibitorsinlungcancer
AT chhavijain roleofimmunecheckpointinhibitorsinlungcancer
AT vamsidharvelcheti roleofimmunecheckpointinhibitorsinlungcancer
_version_ 1724669387615502336

Similar Items